Vistagen Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023
November 10, 2023 at 03:14 am IST
Share
Vistagen Therapeutics, Inc. reported earnings results for the second quarter and six months ended September 30, 2023. For the second quarter, the company reported revenue was USD 0.2777 million compared to negative revenue of USD 0.8925 million a year ago. Net loss was USD 6.59 million compared to USD 17.48 million a year ago. Basic loss per share from continuing operations was USD 0.66 compared to USD 2.54 a year ago.
For the six months, revenue was USD 0.4553 million compared to negative revenue of USD 0.5825 million a year ago. Net loss was USD 13.49 million compared to USD 37.26 million a year ago. Basic loss per share from continuing operations was USD 1.55 compared to USD 5.41 a year ago.
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company focuses on transforming the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. It is advancing therapeutics for treatment of anxiety, depression, and multiple CNS disorders. Its pipeline includes six clinical-stage product candidates, including fasedienol (PH94B), itruvone (PH10), PH15, PH80, and PH284, each an investigational agent belonging to a new class of drugs known as pherines, as well as AV-101, which is an oral antagonist of the N-methyl-D-aspartate receptor (NMDAR). Pherines, which are administered as low-dose nasal sprays, are designed with a rapid-onset mechanism of action that activates chemosensory neurons in the nasal cavity and can impact key neural circuits in the brain without systemic uptake or direct activity on CNS neurons in the brain. PH94B is a synthetic investigational pherine from the androstane family.